Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $206.76 | 8 | 94.5% |
| Education | $11.92 | 1 | 5.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ADC Therapeutics America, Inc. | $84.32 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $21.61 | 1 | $0 (2019) |
| Tempus AI, Inc | $21.08 | 1 | $0 (2024) |
| Lilly USA, LLC | $19.56 | 1 | $0 (2022) |
| Eisai Inc. | $18.18 | 1 | $0 (2017) |
| GENZYME CORPORATION | $15.27 | 1 | $0 (2017) |
| PFIZER INC. | $13.92 | 1 | $0 (2022) |
| Millennium Pharmaceuticals, Inc. | $12.82 | 1 | $0 (2017) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.08 | 1 | Tempus AI, Inc ($21.08) |
| 2022 | $117.80 | 3 | ADC Therapeutics America, Inc. ($84.32) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $21.61 | 1 | E.R. Squibb & Sons, L.L.C. ($21.61) |
| 2017 | $46.27 | 3 | Eisai Inc. ($18.18) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/15/2024 | Tempus AI, Inc | — | Food and Beverage | In-kind items and services | $21.08 | General |
| 11/17/2022 | PFIZER INC. | XALKORI (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $13.92 | General |
| Category: ONCOLOGY | ||||||
| 06/21/2022 | Lilly USA, LLC | CYRAMZA (Drug), VERZENIO, RETEVMO | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: Oncology | ||||||
| 04/29/2022 | ADC Therapeutics America, Inc. | — | Food and Beverage | Cash or cash equivalent | $84.32 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/04/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $21.61 | General |
| Category: Oncology | ||||||
| 11/10/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $15.27 | General |
| Category: ONCOLOGY | ||||||
| 09/14/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: Oncology | ||||||
| 02/09/2017 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | Cash or cash equivalent | $18.18 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 340 | 583 | $104,393 | $35,426 |
| 2022 | 6 | 314 | 462 | $111,243 | $40,706 |
| 2021 | 5 | 291 | 483 | $118,471 | $45,888 |
| 2020 | 9 | 244 | 412 | $87,015 | $32,083 |
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 47 | 108 | $27,894 | $10,005 | 35.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 72 | 116 | $19,488 | $7,074 | 36.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 36 | 49 | $12,152 | $4,579 | 37.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 51 | $9,078 | $3,555 | 39.2% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 52 | 53 | $12,413 | $3,542 | 28.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 15 | 25 | $6,475 | $1,750 | 27.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 11 | $4,807 | $1,449 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 13 | 13 | $4,576 | $1,314 | 28.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 26 | $4,628 | $1,260 | 27.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 34 | 131 | $2,882 | $898.80 | 31.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 76 | 152 | $36,632 | $13,039 | 35.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 57 | 104 | $24,440 | $9,698 | 39.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 74 | 78 | $23,503 | $8,818 | 37.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 53 | $8,904 | $3,099 | 34.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 27 | 33 | $7,755 | $2,612 | 33.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $5,984 | $1,765 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 23 | 25 | $4,025 | $1,676 | 41.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 88 | 215 | $51,815 | $18,178 | 35.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 77 | 125 | $28,000 | $12,348 | 44.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 67 | 69 | $21,318 | $7,893 | 37.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $10,912 | $4,386 | 40.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 27 | 42 | $6,426 | $3,082 | 48.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 53 | 150 | $25,200 | $9,200 | 36.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 58 | 107 | $22,791 | $8,583 | 37.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 27 | 45 | $10,845 | $3,765 | 34.7% |
About Dr. Ignatius Nyatsanza, M.D
Dr. Ignatius Nyatsanza, M.D is a Hematology & Oncology healthcare provider based in Oklahoma City, Oklahoma. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/24/2008. The National Provider Identifier (NPI) number assigned to this provider is 1891945184.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ignatius Nyatsanza, M.D has received a total of $218.68 in payments from pharmaceutical and medical device companies, with $21.08 received in 2024. These payments were reported across 9 transactions from 9 companies. The most common payment nature is "Food and Beverage" ($206.76).
As a Medicare-enrolled provider, Nyatsanza has provided services to 1,189 Medicare beneficiaries, totaling 1,940 services with total Medicare billing of $154,103. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Oklahoma City, OK
- Active Since 09/24/2008
- Last Updated 11/10/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1891945184
Products in Payments
- OPDIVO (Biological) $21.61
- CYRAMZA (Drug) $19.56
- Lenvima (Drug) $18.18
- JEVTANA (Drug) $15.27
- XALKORI (Drug) $13.92
- NINLARO (Drug) $12.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Oklahoma City
Robert Reynolds, Md, MD
Hematology & Oncology — Payments: $14,579
Philip Comp, Md, MD
Hematology & Oncology — Payments: $13,151
Dr. Charles Hollen, M.d, M.D
Hematology & Oncology — Payments: $12,135
Jennifer Holter-Chakrabarty, Md, MD
Hematology & Oncology — Payments: $11,994
Dr. Saadia Chohan, Md, MD
Hematology & Oncology — Payments: $11,197
Abby Bova, Md, MD
Hematology & Oncology — Payments: $5,791